News

Munich and Europe: European EUROCALIN Consortium with a strong Munich hallmark

A new research consortium with a strong Munich involvement will be working on a Pieris AG, Freising, drug candidate, which is currently at the preclinical stage of development, to take it through its clinical trial stage in the next four years.

Also involved in the project along with Pieris (IZB, Freising) are Coriolis GmbH (domiciled in the IZB, Martinsried) and, from Munich, FGK Clinical Research and Technische Universität München. Further partners are the Medical University of Innsbruck (Austria); Radboud University Nijmegen Medical Center (Netherlands); Covance Laboratories Ltd. (UK); Antitope Ltd. (UK); FUJIFILM Diosynth Biotechnologies Ltd. (UK) and ConsulTech GmbH (Germany).

EUROCALIN stands for “EUROpean Consortium for AntiCALINs as next generation high-affinity protein therapeutics”. The funding of around € 6 million is to be used to take the original advance development of anticalins as “mini antibodies”, which had received a considerable boost through the work of Professor Arne Skerra, Weihenstephan Science Center of TU, to the next development stage.


The announcement of EU FP7 funding for the EUROCALIN consortium, which is lead-managed by Pieris, to develop a proprietary Pieris-owned anti-hepcidin Anticalin programme is also having a positive effect on Pieris’s possibilities for advancing its pipeline. Recently, the company’s most advanced compound successfully completed a clinical Phase I trial. A second one is planned to enter clinical trials in 2013, and up to two more are expected to reach this milestone in 2014.
Stephen Yoder, CEO Pieris, comments: “Each of these programmes represents a therapeutic first-in-class or best-in-class solution, and we are looking forward to being able to announce important progress in the development of these assets in the next six months.”

You can find a video-interview with Stephen Yoder in our TV-channel:

http://www.bio-m.org/index.php?id=52

 

Further information can be obtained:

www.pieris-ag.com


Newsletter

Subscribe

Archive